Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

UPDATE: On May 8, the Lupus Foundation of America submitted comments on CMS' interim final rule commending the agency for taking swift action to ensure continuity of care for people with lupus amid ...

People with lupus often need to use medicine to manage their symptoms. Although there are many oral medicines that treat lupus, some people with moderate to severe lupus may not get enough benefit ...

Paula Bruton Shepard had difficulty getting monthly infusions to treat her lupus. Her local hospital, in Bolivar, Missouri, had the drug. But her insurer required it to be sent through a separate ...

The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

People with lupus often need to use medicines to manage their symptoms. Although there are many oral medicines that treat lupus, some people with more severe symptoms may not get enough benefit from ...

Australian researchers may have found a breakthrough treatment for lupus. In a study published in Nature Communications on Feb. 6, scientists at Monash University revealed that they were able to "fix" ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Obinutuzumab provides sustained clinical benefit through ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

Please provide your email address to receive an email when new articles are posted on . Fluid cognition impairment was more common among patients with systemic lupus erthematosus, particularly in ...